Study of next treatments after targeted therapy resistance for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic breast cancer (cancer that has spread).
- You have been treated with a targeted therapy like a CDK4/6 inhibitor, PIK3CA inhibitor, or trastuzumab deruxtecan (T-DXd).
- Your cancer grew or came back during or after that targeted therapy.
- You have started a new treatment (chemo, hormone therapy, targeted therapy, or a mix) after the resistance.
- You have had at least one follow-up visit after starting the new treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a sequence of different treatments for breast cancer that has spread, based on how the cancer evolves. The goal is to find a personalized treatment plan that may work better over time.
This study looks at how patients with advanced breast cancer (HER2-positive type) respond to anti-HER2 drugs over time. Researchers in Kazakhstan are reviewing medical records to understand which treatments work best and help improve care for future patients.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.